Description

Founded in 1998 and headquartered in Qingdao, China, Huaren Pharmaceutical Co., Ltd. is a key player in the Chinese market, primarily focusing on the production and distribution of non-PVC soft bag intravenous solutions. Its comprehensive pharmaceutical offerings include a variety of injectable drugs such as doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, caffeine citrate, sodium chloride, glucose, glucose sodium potassium chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterile water. Beyond these specific formulations, the company also manufactures therapeutic infusion products designed for critical medical applications, including blood volume expansion, hemostasis, nervous and circulatory system support, anti-infective treatments, anti-hepatitis and hepatitis adjuvant therapies, anti-tumor interventions, and carbohydrate metabolism management. In addition to pharmaceuticals, Huaren Pharmaceutical supplies a broad range of medical devices. These encompass single-use items like incision retractors, cannula puncture tools, and specimen extractors, as well as abdominal suction tubes, incision retractor protectors, iodine solution protective caps, and slip pads. The company's device portfolio further extends to respiratory oscillation expectoration machines and various protective masks, including cup-type, foldable disposable, and medical-grade protective masks. The company's operations also diversify into pharmaceutical packaging materials, providing components such as rubber stoppers, cartons, and membranes. Furthermore, it produces rinsing fluids and Active Pharmaceutical Ingredient (API) series products, alongside venturing into the food and beverage sector and offering medical-grade skin care products.